Article
Investigational New Drug Application Submitted by Omega Represents the First Epigenomic Controller in a New Class of Programmable mRNA Therapeutics Excerpt from the Press Release: CAMBRIDGE, Mass., June 15, 2022 /PRNewswire/ — Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced the submission of an Investigational New Drug (IND) application to the U.S. Food and Drug…
Read More
Pivotal trial to study the safety and efficacy of sacral nerve stimulation in patients with urinary urgency incontinence symptoms Excerpt from the Press Release: SAN JOSE, Calif., June 14, 2022 /PRNewswire/ — Neuspera® Medical, a medical device company developing implantable devices for patients battling chronic illnesses, today announced it will begin enrollment in its pivotal clinical trial…
Read More
Excerpt from the Press Release: SAN DIEGO, June 14, 2022 /PRNewswire/ — HUYABIO International today announced that the first three patients had been dosed in an ongoing Phase 2 study of HUYABIO’s novel drug for pharmacological cardioversion of atrial fibrillation (AF). Dr. Mireille Gillings, President, CEO & Executive Chair, said, “We are excited to proceed with…
Read More
Excerpt from the Press Release: Alzheimer’s disease is the most common form of dementia, one of the major causes of dependency and disability in older adults. Though advances have been made in understanding the harrowing brain disease, diagnostic tests are currently limited and there are no treatments. Now, a uOttawa Faculty of Medicine assistant professor and a…
Read More
At 22, with her degree from McMaster’s program in Integrated Biomedical Engineering and Health Sciences in hand, Lianna Genovese already holds two patents in the United States and Canada, as well as four trademarks. Excerpt from the Press Release: Passion, drive and a good idea turned Lianna Genovese into a corporate entrepreneur long before she…
Read More
Cloud-native Alissa data analysis SaaS platform empowers clinical labs and researchers to scale operations with parallel analysis of genomic data Excerpt from the Press Release: Agilent Technologies Inc. (NYSE: A), a global leader in genomics technology, today announced it will use Amazon Elastic Compute Cloud (Amazon EC2) G5g instances powered by Amazon Web Services (AWS)…
Read More
First study subject has been dosed in a single dose/dose escalation study of recently diagnosed COVID-19 patients Study will evaluate safety as the primary end point with pharmacokinetics (PK) and virology as secondary assessments Excerpt from the Press Release: EXTON, Pa.–(BUSINESS WIRE)–Immunome, Inc. (Nasdaq: IMNM), a biopharmaceutical company that utilizes its human memory B cell…
Read More
Excerpt from the Press Release: Now has orphan drug designation for SCLC and AML MADRID, Spain and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) — Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company leveraging epigenetics to develop therapies in diseases with strong unmet medical need, announced today that the U.S. Food and…
Read More
Cemdisiran Treatment Resulted in a 37 Percent Mean Reduction in 24-Hour Urine Protein to Creatinine Ratio, Relative to Placebo – a Key Prognostic Marker of Progression to End-Stage Kidney Disease in Patients with IgA Nephropathy – – Acceptable Safety Profile, Supporting Continued Clinical Development – – Full Results to Be Presented at Future Medical Congress –…
Read More
Excerpt from the Press Release: SAN DIEGO, June 09, 2022 (GLOBE NEWSWIRE) — Cend Therapeutics, Inc. (“Cend”) today announced that the first patient has been treated in the Phase 2b study of CEND-1, Cend’s lead investigational drug, in patients with first-line metastatic pancreatic ductal adenocarcinoma. The ASCEND trial is a 125-patient, double-blind, randomized, placebo-controlled clinical…
Read More